Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Erythrocyte membrane protein band 4.1-like 4A (EPB41L4A)
- Target
- EPB41L4A
- Molecular classification
- FERM (Four-point-one, Ezrin, Radixin, Moesin) domain protein superfamily, Membrane-associated protein, Cytoskeletal regulator
01
Overview
Erythrocyte membrane protein band 4.1-like 4A (EPB41L4A) is a member of the FERM domain (Four-point-one, Ezrin, Radixin, Moesin) superfamily of membrane-associated proteins.[2][3][4][5] EPB41L4A regulates cytoskeleton–membrane interactions, intracellular trafficking, and participates in critical signaling pathways, notably the WNT/β-catenin pathway. It serves a tumor-suppressive role by regulating cell proliferation, migration, and invasion; its antisense long noncoding RNAs modulate metabolic reprogramming and sensitivity to chemotherapy.[1][2][5] EPB41L4A has implications in various diseases, including cancer, neurodevelopmental disorders, and genetic syndromes. Despite its important biological and prognostic roles, no drugs are known to target it directly, nor is it classified as a standard therapeutic target at present.[1][2][5]
- Other names
- Band 4.1-like protein 4AEPB41L4NBL4Protein NBL4Erythrocyte protein band 4.1-like 4band 4.1-like protein 4Aerythrocyte membrane protein band 4.1 like 4A
02
Mechanism of action
Not applicable (currently no drugs directly target EPB41L4A)
03
Biological functions
Regulation of cytoskeleton–membrane interactionsIntracellular traffickingModulation of WNT/β-catenin signalingRegulation of cell proliferation, migration, and differentiationTumor suppression (inhibition of proliferation, migration, invasion)
04
Disease associations
Cancer (breast, renal, lung, head and neck, multiple myeloma, papillary thyroid carcinoma, neuroblastoma)Genetic susceptibility to congenital keratosis, colon, nerve/brain muscle diseasesFrontotemporal dementia and/or amyotrophic lateral sclerosis 7Failure of tooth eruption, primary
05
Safety considerations
None specifically reported; not a therapeutic target
06
Biomarkers
Prognostic biomarker in multiple myeloma (high expression predicts favorable outcomes)Predictive marker for chemotherapy resistance in breast cancer (role for lncRNA EPB41L4A-AS2)Biomarker for prognosis in pediatric neuroblastoma
Beyond the preview
Go deeper on Erythrocyte membrane protein band 4.1-like 4A (EPB41L4A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Erythrocyte membrane protein band 4.1-like 4A (EPB41L4A).